TNF and rheumatoid arthritis: JAK inhibition has demonstrated high efficacy, as approximately 60–70 % RA patients experience clinical improvement with at least 20 % response according to American College of Rheumatology criteria (ACR20 response) [12], even in non-responders to anti-TNF treatment (ACR20 of 48 %) [13].